Arcutis Biotherapeutics up after Q1 revenue rises
14/05/2024 22:07
** Drugmaker Arcutis Biotherapeutics' ARQT.O shares rise
16.9% to $9.50 after market
** Company posts Q1 revenue of $49.6 mln vs $2.8 mln a year
earlier
** Company posts Q1 net product revenue of $21.6 mln from
its psoriasis and eczema treatment cream Zoryve vs $2.8 mln a
year earlier
** Arcutis records $28 mln in revenue from upfront and
milestone payments in Q1
** Company posts Q1 net loss of $35.4 mln vs loss of $80.1
mln a year earlier
** Stock has more than doubled YTD
(Reporting by Sneha S K in Bengaluru)
((Sneha.SK@thomsonreuters.com))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf